Trial Profile
A multicentre, two-part, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, tolerability and pharmacokinetics of the iNOS inhibitor GW274150 administered up to 120mg daily for 12 weeks in the prophylactic treatment of migraine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs GW 274150 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors GSK
- 15 Oct 2008 Actual start date changed from Jan 2007 to Oct 2005 as reported by ClinicalTrials.gov
- 09 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
- 01 Jun 2007 Status change from recruiting to in progress.